Golexin (Goserelin) 3.6mg and LA 10.8mg

Golexin (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Golexin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females.

Share Now

Name Golexin L.A
Description (i) Treatment of prostate cancer in the following settings (see also section 5.1):

  • In the treatment of metastatic prostate cancer where Golexin has demonstrated comparable survival benefits to surgical castrations (see section 5.1)
  • In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Golexin has demonstrated comparable survival benefits to an anti-androgen (see section 5.1)
  • As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Golexin has demonstrated improved disease-free survival and overall survival (see section 5.1)
  • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Golexin has demonstrated improved disease-free survival (see section 5.1)
  • As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Golexin has demonstrated improved disease-free survival (see section 5.1)

(ii) Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
(iii) Golexin 3.6 mg is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.
(iv) Endometriosis: In the management of endometriosis, Golexin alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
(v) Endometrial thinning: Golexin is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
(vi) Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.
(vii) Assisted reproduction: Pituitary downregulation in preparation for superovulation.

Active Ingredient Goserelin
Indication Golexin (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Golexin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Golexin, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.
Strengths 3.6 mg and 10.8 mg